Exciting Presentation on Denifanstat at AASLD 2025
Sagimet Biosciences Inc. (NASDAQ: SGMT), a pioneering clinical-stage biopharmaceutical company, is gearing up for a major presentation at the upcoming AASLD - The Liver Meeting 2025. This prominent event will run from November 7 to November 11, 2025, and is highly regarded in the field of liver disease research.
Significant Findings from Phase 2b Study
Recent analyses from the Phase 2b FASCINATE-2 study have demonstrated promising results for denifanstat, showcasing its potential in improving fibrosis in patients suffering from advanced fibrosis linked to metabolic dysfunction. The data will be showcased as a Poster of Distinction at the conference, promising to add significant insights to the ongoing discourse on treatment options for metabolic dysfunction-associated steatohepatitis (MASH).
Poster Session Details
The poster presentation will cover critical findings that highlight how denifanstat achieved a notable improvement in fibrosis staging for patients classified as F3 MASH, as well as improvements in liver fibrosis biomarkers in patients categorized under qFibrosis stage 4 MASH. Details for the presentation are as follows:
Title of the Presentation
Denifanstat elicited a significant ?2-stage improvement in fibrosis in F3 MASH patients and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of phase 2b FASCINATE-2 study.
Session Information
The session will focus on MASLD/MASH therapeutics, offering a platform for researchers and clinicians to discuss new agents alongside existing treatments.
Presentation Schedule
Set for November 10, 2025, from 8:00 AM to 5:00 PM ET, this session provides ample opportunity for attendees to engage with the latest scientific findings in liver disease therapies.
Meet the Presenting Author
The presentation will be delivered by Dr. Rohit Loomba, a distinguished expert from the University of California San Diego. His involvement underscores the importance of this research in advancing treatment methodologies for MASH.
Denifanstat: A Transformative Drug
Denifanstat, the lead candidate from Sagimet, represents a new horizon in treating metabolic diseases linked with excessive palmitate production. It specifically targets the fatty acid synthase (FASN) enzyme, which is pivotal for various metabolic processes. This oral medication is taken once daily, making it accessible for patients and enhancing compliance.
Regulatory Progress and Clinical Trials
The FDA has granted Breakthrough Therapy designation to denifanstat for treating patients with moderate to advanced non-cirrhotic MASH. Recent interactions with the FDA reaffirmed the positive steps Sagimet is making toward further clinical development.
Current and Future Trials
Recently, Sagimet launched a Phase 1 clinical trial focusing on a combination of denifanstat and resmetirom, aimed at offering hope to those coping with MASH. Furthermore, an initial clinical trial with another oral FASN inhibitor, TVB-3567, is also underway, which is intended for acne treatment in the U.S.
Understanding MASH
Metabolic dysfunction-associated steatohepatitis (MASH) poses a serious health crisis, affecting over 265 million people globally. Patients experience a dangerous buildup of fat in the liver alongside inflammation and fibrosis. The need for effective treatments is urgent, especially for those in advanced fibrosis stages.
Risks Associated with MASH
Individuals with moderate to severe MASH are at the highest risk for severe outcomes, including liver-related complications such as decompensation and even the necessity for liver transplants. Current treatment options remain limited, especially for advanced fibrosis, emphasizing the potential impact of Sagimet's clinical findings.
About Sagimet Biosciences
As an innovative biopharmaceutical company, Sagimet Biosciences is at the forefront of developing targeted therapies aimed at addressing metabolic and fibrotic pathways in various liver diseases, particularly focusing on the implications of fatty acid synthesis dysregulation.
Contact Information
For further inquiries, investors can reach out to Joyce Allaire via JAllaire@LifeSciAdvisors.com. Media inquiries can be directed to Michael Fitzhugh at mfitzhugh@lifescicomms.com.
Frequently Asked Questions
What will Sagimet present at AASLD 2025?
Sagimet will showcase findings from its Phase 2b study on denifanstat, focusing on its significant impact on fibrosis improvement.
Who is the presenting author for the research?
Dr. Rohit Loomba from the University of California San Diego will present the research findings.
What is the significance of denifanstat?
Denifanstat is a novel drug that targets fatty acid synthase to treat metabolic dysfunction associated with liver diseases.
What is MASH?
MASH stands for metabolic dysfunction-associated steatohepatitis, a severe liver disease characterized by fat buildup and inflammation.
How can I learn more about Sagimet Biosciences?
Visit their official website at www.sagimet.com for more information.
